A5025229446- Botulinum Toxin and Related Neurological Disorders
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Genetic Neurodegenerative Diseases
- Cancer Treatment and Pharmacology
- Neuroscience and Neuropharmacology Research
- Pain Mechanisms and Treatments
- Stroke Rehabilitation and Recovery
- Cerebral Palsy and Movement Disorders
- Neurogenesis and neuroplasticity mechanisms
- Hereditary Neurological Disorders
- Plant-based Medicinal Research
- Parkinson's Disease and Spinal Disorders
- Cardiovascular Syncope and Autonomic Disorders
- Autism Spectrum Disorder Research
- Restless Legs Syndrome Research
- Neurological and metabolic disorders
- Cardiac Arrhythmias and Treatments
- Ophthalmology and Eye Disorders
- Voice and Speech Disorders
- Dysphagia Assessment and Management
- Autoimmune Neurological Disorders and Treatments
- Heart Rate Variability and Autonomic Control
- Dupuytren's Contracture and Treatments
- Trigeminal Neuralgia and Treatments
Loma Linda University
2016-2025
University Health System
2018-2025
California State University, San Bernardino
2025
Loma Linda University Medical Center
2016-2024
Loma Linda University Health Care
2023
Southern California University for Professional Studies
2021
University of Southern California
2021
Geisinger Health System
2021
University of California System
2021
Marshall B. Ketchum University
2019
Estimates of the spectrum and frequency pathogenic variants in Parkinson's disease (PD) different populations are currently limited biased. Furthermore, although therapeutic modification several genetic targets has reached clinical trial stage, a major obstacle conducting these trials is that PD patients largely unaware their status and, therefore, cannot be recruited. Expanding number investigated PD-related genes including related to disorders with overlapping features large,...
ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety 2 doses DaxibotulinumtoxinA for Injection (DAXI), novel botulinum toxin type A formulation in participants with cervical dystonia (CD).
Background. Novel rehabilitation strategies have demonstrated potential benefits for motor and non-motor symptoms of Parkinson's disease (PD). Objective. To compare the effects Lee Silverman Voice Therapy BIG (LSVT therapy) versus a general exercise program (combined treadmill plus seated trunk limb exercises) on PD. Methods. Eleven patients with early-mid stage PD participated in prospective, double-blinded, randomized clinical trial. Both groups received 16 one-hour supervised training...
RimabotulinumtoxinB (RIMA) may be preferable as an anti-sialorrhea treatment compared with current oral anticholinergic drugs in people neurological disorders.To assess the safety, efficacy, and tolerability of RIMA injections for sialorrhea adults.This randomized, parallel, double-blind, placebo-controlled clinical trial 2500 U 3500 was conducted from November 14, 2013, to January 23, 2017. A total 249 adult patients troublesome secondary any disorder or cause were screened. Of them, 13...
Cognitive impairment is a common nonmotor symptom among individuals with Parkinson's disease (PD). Although cognitive generally develops progressively, PD-associated mild (PD-MCI) may revert to being cognitively normal (CN), which referred as PD-MCI reversion. Previous studies are inconsistent in whether reverters at greater risk for recurrence relative CN individuals. Even less known about how compare or nonreverters terms of neurodegenerative biomarkers. The authors examined group...
Background Continuous subcutaneous apomorphine infusion (CSAI) has been used globally since the 1980s for Parkinson disease (PD) motor fluctuations but not available in United States (US). Objective Evaluate CSAI US setting. Methods This open-label study (NCT02339064) enrolled patients with PD experiencing ≥3 hours (h) daily OFF time despite optimized levodopa and current/prior use of at least one other adjunctive therapy. was initiated a 1–2 mg bolus followed by 1 mg/h titrated to optimal...
Abstract Active caspase‐3 immunoreactivity was detected in the rat forebrain proliferative regions at birth and remained high these areas for about 2 weeks, during which period labeled cells were present centroperipherally across olfactory bulb. By end of third postnatal week, only a small number immunolabeled structures. immunolabeling localized mostly to cell nuclei co‐localized partially with TuJ1 NeuN immunoreactivity, but not glial fibrially acidic protein, OX‐42, γ‐aminobutyric acid,...
Background. Iron is considered to lead neurodegeneration and has been hypothesized as a possible cause of Parkinson's disease (PD). Susceptibility-weighted imaging (SWI) powerful tool measure phase related iron content brain. Methods. Twelve de novo patients with PD were recruited from the Movement Disorders Clinic, Department Neurology, Loma Linda University. age- sex-matched non-PD subjects neurology clinic controls. Using SWI, was estimated different brain regions interest (ROIs)....
OnabotulinumtoxinA reduces muscle hypertonia associated with poststroke spasticity (PSS). PSS manifests as several common postures.To define treatment paradigms for upper-limb postures.Modified Delphi method.Expert panel.Ten injectors experienced in the and clinical research of (physiatrists neurologists) were invited to participate panel.The panel reviewed an electronic worksheet postures onabotulinumtoxinA (Round 1). During Round 2, members discussed person 1 results voted until consensus...
An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the 'Save PDF' action button.